• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Disposition of ifosfamide in patients receiving ifosfamide infusion therapy for the treatment of cervical carcinoma.

作者信息

Pearcey R, Calvert R, Mehta A

机构信息

University Department of Radiotherapy, Cookridge Hospital, Leeds, UK.

出版信息

Cancer Chemother Pharmacol. 1988;22(4):353-5. doi: 10.1007/BF00254245.

DOI:10.1007/BF00254245
PMID:3168149
Abstract

The disposition of ifosfamide was investigated in nine patients receiving a total of 23 72-h infusions. There was no linear relationship between steady-state plasma concentrations and either vomiting or CNS toxicity. The steady-state plasma concentrations were reproducible within patients, but there was a wide variation between patients. The progress of the disease did not affect the disposition of ifosfamide.

摘要

相似文献

1
Disposition of ifosfamide in patients receiving ifosfamide infusion therapy for the treatment of cervical carcinoma.
Cancer Chemother Pharmacol. 1988;22(4):353-5. doi: 10.1007/BF00254245.
2
Phase II study of carboplatin/ifosfamide in untreated advanced cervical cancer.卡铂/异环磷酰胺治疗未经治疗的晚期宫颈癌的II期研究。
Cancer Chemother Pharmacol. 1990;26 Suppl:S33-5. doi: 10.1007/BF00685414.
3
Efficacy and tolerability of paclitaxel, ifosfamide, and cisplatin as a neoadjuvant chemotherapy in locally advanced cervical carcinoma.紫杉醇、异环磷酰胺和顺铂作为局部晚期宫颈癌新辅助化疗的疗效和耐受性
J Gynecol Oncol. 2015 Apr;26(2):118-24. doi: 10.3802/jgo.2015.26.2.118. Epub 2015 Feb 4.
4
The role of ifosfamide in cervical cancer.异环磷酰胺在宫颈癌中的作用。
Semin Oncol. 1989 Feb;16(1 Suppl 3):60-7.
5
[Combination chemotherapy with nedaplatin, bleomycin and ifosfamide for advanced cervical cancer of the uterus--a preliminary study for phase III clinical study].奈达铂、博来霉素与异环磷酰胺联合化疗治疗晚期子宫颈癌——一项III期临床研究的初步研究
Gan To Kagaku Ryoho. 1997 Aug;24(10):1285-93.
6
Pharmacokinetics of ifosfamide and its enantiomers following a single 1 h intravenous infusion of the racemate in patients with small cell lung carcinoma.在小细胞肺癌患者中单次静脉输注消旋体1小时后异环磷酰胺及其对映体的药代动力学。
Br J Clin Pharmacol. 1995 Apr;39(4):452-5. doi: 10.1111/j.1365-2125.1995.tb04477.x.
7
A phase I study of ifosfamide, paclitaxel, and carboplatin in advanced and recurrent cervical cancer.异环磷酰胺、紫杉醇和顺铂用于晚期和复发性宫颈癌的I期研究。
Gynecol Oncol. 2004 Nov;95(2):347-51. doi: 10.1016/j.ygyno.2004.07.037.
8
Cisplatin-ifosfamide as neoadjuvant chemotherapy in stage IIIB cervical uterine squamous-cell carcinoma.顺铂-异环磷酰胺作为ⅢB期子宫颈鳞状细胞癌的新辅助化疗
Cancer Chemother Pharmacol. 1990;26 Suppl:S36-8. doi: 10.1007/BF00685415.
9
Early phase II Gynecologic Oncology Group experience with ifosfamide/mesna in gynecologic malignancies.妇科肿瘤学组关于异环磷酰胺/美司钠用于妇科恶性肿瘤的II期早期经验。
Cancer Chemother Pharmacol. 1990;26 Suppl:S55-8. doi: 10.1007/BF00685421.
10
Concomitant chemobrachyradiotherapy with ifosfamide and cisplatin followed by consolidation chemotherapy for women with locally advanced carcinoma of the uterine cervix--final results of a prospective phase II-study.异环磷酰胺和顺铂同步放化疗后巩固化疗用于局部晚期宫颈癌女性患者——一项前瞻性II期研究的最终结果
Gynecol Oncol. 2006 Nov;103(2):494-9. doi: 10.1016/j.ygyno.2006.03.060. Epub 2006 Jun 30.

引用本文的文献

1
Clinical pharmacokinetics and pharmacodynamics of ifosfamide and its metabolites.异环磷酰胺及其代谢产物的临床药代动力学和药效学
Clin Pharmacokinet. 2001 Jan;40(1):41-62. doi: 10.2165/00003088-200140010-00004.
2
Toxicity of ifosfamide, cyclophosphamide and their metabolites in renal tubular cells in culture.异环磷酰胺、环磷酰胺及其代谢产物对培养的肾小管细胞的毒性作用。
Pediatr Nephrol. 1994 Apr;8(2):157-63. doi: 10.1007/BF00865466.
3
The pharmacokinetics of ifosfamide given as short and long intravenous infusions in cancer patients.

本文引用的文献

1
Ifosfamide/mesa and encephalopathy.异环磷酰胺/美司钠与脑病
Lancet. 1985 Mar 30;1(8431):752. doi: 10.1016/s0140-6736(85)91288-7.
2
Encephalopathy associated with ifosphamide/mesna therapy.与异环磷酰胺/美司钠治疗相关的脑病。
Lancet. 1985 Feb 16;1(8425):406-7. doi: 10.1016/s0140-6736(85)91432-1.
3
Pharmacokinetics of intravenous cyclophosphamide in man, estimated by gas-liquid chromatography.通过气液色谱法估算人静脉注射环磷酰胺的药代动力学。
癌症患者中短时间和长时间静脉输注异环磷酰胺的药代动力学。
Br J Clin Pharmacol. 1991 Jan;31(1):77-82. doi: 10.1111/j.1365-2125.1991.tb03860.x.
4
Urinary excretion of the enantiomers of ifosfamide and its inactive metabolites in children.
Cancer Chemother Pharmacol. 1991;28(6):455-60. doi: 10.1007/BF00685822.
5
Ifosfamide pharmacokinetics.
Invest New Drugs. 1991 Nov;9(4):305-11. doi: 10.1007/BF00183570.
6
Dosing and side-effects of ifosfamide plus mesna.异环磷酰胺加美司钠的剂量及副作用
J Cancer Res Clin Oncol. 1991;117 Suppl 4(Suppl 4):S164-86. doi: 10.1007/BF01613224.
7
Ifosfamide/mesna. A review of its antineoplastic activity, pharmacokinetic properties and therapeutic efficacy in cancer.异环磷酰胺/美司钠。关于其抗肿瘤活性、药代动力学特性及在癌症治疗中疗效的综述。
Drugs. 1991 Sep;42(3):428-67. doi: 10.2165/00003495-199142030-00006.
Cancer Chemother Pharmacol. 1978;1(4):229-31. doi: 10.1007/BF00257155.